JPMorgan reports 5.2% stake in LB Pharmaceuticals

JPMorgan Chase & Co. reports beneficial ownership of 1,497,293 shares of LB Pharmaceuticals Inc. common stock, representing 5.2% of the outstanding class.

Accepted by SEC EDGAR 07/16/2026 - 04:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

JPMorgan Chase & Co. reports beneficial ownership of 1,497,293 shares of LB Pharmaceuticals Inc. common stock, representing 5.2% of the outstanding class. The securities are LB Pharmaceuticals common stock with a par value of $0.0001 per share.

JPMorgan has sole voting power over 1,379,375 shares and sole dispositive power over all 1,497,293 shares reported, with no shared voting or dispositive power. The holdings are attributed to subsidiaries including JPMorgan Chase Bank, National Association, and J.P. Morgan Investment Management Inc.

Key Figures

Beneficial ownership: 1,497,293 shares Percent of class: 5.2 % Sole voting power: 1,379,375 shares +2 more

5 metrics

Beneficial ownership 1,497,293 shares LB Pharmaceuticals common stock reported by JPMorgan Chase & Co.

Percent of class 5.2 % Portion of LB Pharmaceuticals common stock class held by JPMorgan

Sole voting power 1,379,375 shares Shares for which JPMorgan can solely vote or direct the vote

Sole dispositive power 1,497,293 shares Shares for which JPMorgan has sole power to dispose or direct disposition

Reporting date 06/30/2026 Date associated with the Schedule 13G ownership report

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, parent holding company, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: 1,497,293"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"Sole Voting Power 1,379,375.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"Sole Dispositive Power 1,497,293.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

parent holding company regulatory

"If a parent holding company has filed this schedule"

Schedule 13G regulatory

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in LBRX does JPMorgan Chase & Co. report in this Schedule 13G?

JPMorgan Chase & Co. reports beneficial ownership of 1,497,293 LB Pharmaceuticals (LBRX) common shares, representing 5.2% of the class. This indicates a significant institutional position, with the stake disclosed as of the June 30, 2026 reporting date.

How many LBRX shares does JPMorgan have sole voting power over?

JPMorgan reports sole voting power over 1,379,375 LB Pharmaceuticals (LBRX) shares. It reports no shared voting power, meaning all voting authority for the reported position rests solely with JPMorgan or its relevant subsidiaries.

What is JPMorgan’s sole dispositive power over LBRX shares?

JPMorgan has sole dispositive power over 1,497,293 LB Pharmaceuticals (LBRX) shares. It reports zero shared dispositive power, indicating exclusive authority to decide if and when these shares are sold or otherwise disposed of.

Which JPMorgan subsidiaries are identified as holding LBRX securities?

The Schedule 13G identifies JPMorgan Chase Bank, National Association and J.P. Morgan Investment Management Inc. as subsidiaries related to the LB Pharmaceuticals (LBRX) holdings. These entities are associated with acquiring or holding the reported securities.

What class of LB Pharmaceuticals (LBRX) securities does JPMorgan hold?

The reported position is in LB Pharmaceuticals Common Stock with a par value of $0.0001 per share. The disclosure covers this single class of equity securities, identified by CUSIP number 50180M108.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

LB PHARMACEUTICALS INC

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

50180M108

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 50180M108

1

Names of Reporting Persons

JPMORGAN CHASE & CO

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,379,375.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,497,293.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,497,293.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: LB PHARMACEUTICALS INC
(b)	Address of issuer's principal executive offices: One Pennsylvania Plaza, Suite 1025, NEW YORK, NEW YORK, 10119.
Item 2.
(a)	Name of person filing: JPMORGAN CHASE & CO.
(b)	Address or principal business office or, if none, residence: 270 Park Avenue, New York, NY 10017
(c)	Citizenship: DE
(d)	Title of class of securities: Common Stock, $0.0001 par value
(e)	CUSIP Number(s): 50180M108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,497,293
(b)	Percent of class: 5.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,379,375
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,497,293
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. JPMorgan Chase Bank, National Association; J.P. Morgan Investment Management Inc.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

JPMORGAN CHASE & CO

Signature:	Rachel Tsvaygoft
Name/Title:	Vice President
Date:	07/16/2026